NKTR - Nektar Therapeutics
IEX Last Trade
1.27
0 0%
Share volume: 560,725
Last Updated: Fri 30 Aug 2024 09:59:49 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$1.27
0.00
0.00%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
| Report Date | 2022-05-06 | 2022-08-05 | 2022-11-04 | 2023-02-28 | 2023-05-10 | 2023-08-09 | 2023-11-08 | 2024-03-05 | |
| Assets | |||||||||
| Total Assets | 1.024 B | 861.987 M | 781.006 M | 710.600 M | 561.743 M | 494.279 M | 442.244 M | 398.033 M | |
| Current Assets | 733.455 M | 665.536 M | 599.483 M | 545.968 M | 491.066 M | 441.058 M | 399.025 M | 330.701 M | |
| Inventories | 15.379 M | 16.969 M | 19.057 M | 19.202 M | 20.235 M | 20.689 M | 15.130 M | 16.101 M | |
| Other Current Assets | 20.831 M | 19.245 M | 22.507 M | 15.808 M | 11.009 M | 9.602 M | 9.033 M | 9.779 M | |
| Short Term Investments | 20.831 M | 19.245 M | 22.507 M | 15.808 M | 11.009 M | 9.602 M | 9.033 M | 9.779 M | |
| Total Receivables | 30.220 M | 10.006 M | 11.532 M | 5.981 M | 2.995 M | 1.335 M | 2.204 M | 1.205 M | |
| Current Cash | 667.025 M | 619.316 M | 546.387 M | 504.977 M | 456.827 M | 409.432 M | 372.658 M | 303.616 M | |
| Total Non-current Assets | 290.661 M | 196.451 M | 181.523 M | 164.632 M | 70.677 M | 53.221 M | 43.219 M | 67.332 M | |
| Property Plant Equipment | 60.980 M | 39.792 M | 36.803 M | 32.451 M | 27.084 M | 22.554 M | 19.949 M | 18.856 M | |
| Other Assets | 1.521 M | 2.234 M | 2.323 M | 2.245 M | 1.406 M | 1.652 M | 4.523 M | 4.644 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 76.501 M | 76.501 M | 76.501 M | 76.501 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.024 B | 861.987 M | 781.006 M | 710.600 M | 561.743 M | 494.279 M | 442.244 M | 398.033 M | |
| Total liabilities | 416.227 M | 403.255 M | 368.783 M | 343.962 M | 320.878 M | 297.321 M | 282.876 M | 267.046 M | |
| Total current liabilities | 105.281 M | 104.985 M | 83.989 M | 68.204 M | 59.879 M | 50.694 M | 52.112 M | 51.269 M | |
| Accounts Payable | 12.617 M | 12.346 M | 5.329 M | 12.980 M | 3.696 M | 2.619 M | 3.288 M | 9.848 M | |
| Other liabilities | 188.308 M | 178.855 M | 168.649 M | 162.929 M | 151.610 M | 140.810 M | 128.571 M | 117.260 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 188.308 M | 178.855 M | 168.649 M | 162.929 M | 151.610 M | 140.810 M | 128.571 M | 117.260 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 607.889 M | 458.732 M | 412.223 M | 366.638 M | 240.865 M | 196.958 M | 159.368 M | 130.987 M | |
| Common stock | 185.848 M | 186.800 M | 187.641 M | 188.263 M | 188.875 M | 189.656 M | 190.406 M | 191.067 M | |
| Retained earnings | -2.923 B | -3.082 B | -3.142 B | -3.201 B | -3.338 B | -3.389 B | -3.435 B | -3.477 B |